Published in Blood on June 29, 2004
Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol (2010) 6.04
Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A (2006) 3.54
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol (2010) 3.38
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell (2010) 3.37
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood (2006) 2.63
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood (2010) 2.06
Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. Clin Cancer Res (2015) 2.00
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect. Cell (2015) 1.94
Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov (2011) 1.89
Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol (2008) 1.87
Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies. PLoS One (2007) 1.61
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood (2014) 1.58
Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood (2012) 1.43
Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica (2009) 1.38
Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood (2008) 1.36
Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther (2011) 1.29
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs (2012) 1.28
Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med (2008) 1.26
Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med (2009) 1.20
Rituximab therapy in nephrotic syndrome: implications for patients' management. Nat Rev Nephrol (2013) 1.18
Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood (2010) 1.17
Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis (2005) 1.14
Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol (2012) 1.12
The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia (2008) 1.05
Aggregation of a multidomain protein: a coagulation mechanism governs aggregation of a model IgG1 antibody under weak thermal stress. Protein Sci (2010) 1.00
Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking. Immunology (2005) 0.98
Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord (2010) 0.98
New antibody approaches to lymphoma therapy. J Hematol Oncol (2014) 0.97
Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. J Clin Immunol (2012) 0.94
Dynamics of macrophage trogocytosis of rituximab-coated B cells. PLoS One (2011) 0.92
Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates. Mol Ther (2010) 0.92
Cell death signaling and anticancer therapy. Front Oncol (2011) 0.91
Regulation of CD20 expression by radiation-induced changes in intracellular redox status. Free Radic Biol Med (2007) 0.91
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism. Ann Oncol (2010) 0.90
γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody. Haematologica (2010) 0.89
Investigational immunotherapeutics for B-cell malignancies. J Clin Oncol (2010) 0.88
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. Br J Haematol (2015) 0.88
Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs (2013) 0.88
Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2. J Biol Chem (2012) 0.88
Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol (2015) 0.87
A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab. Theranostics (2015) 0.86
Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica (2014) 0.85
Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects. Biologics (2007) 0.84
Enhancement of Immune Effector Functions by Modulating IgG's Intrinsic Affinity for Target Antigen. PLoS One (2016) 0.84
Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity. Leukemia (2013) 0.83
Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice. Leukemia (2014) 0.83
Entourage: the immune microenvironment following follicular lymphoma. Blood Cancer J (2012) 0.83
Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Ann Oncol (2010) 0.83
Anti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor Mice. Front Immunol (2014) 0.83
Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma. Clin Exp Immunol (2012) 0.82
Multimodality imaging of coiled-coil mediated self-assembly in a "drug-free" therapeutic system. Adv Healthc Mater (2015) 0.82
Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms. Blood (2016) 0.82
Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cells. J Biol Chem (2012) 0.81
How does B cell depletion therapy work, and how can it be improved? Ann Rheum Dis (2005) 0.80
Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma. Cancer Sci (2014) 0.80
Treatment Strategies for Patients with Diffuse Large B-Cell Lymphoma: Past, Present, and Future. Blood Lymphat Cancer (2012) 0.80
A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma. J Immunother (2013) 0.80
Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions. MAbs (2011) 0.80
Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma. Rheumatol Int (2007) 0.79
CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies. Oncoimmunology (2014) 0.79
Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab. MAbs (2014) 0.79
Use of subsequent PET/CT in diffuse large B-cell lymphoma patients in complete remission following primary therapy. Chin J Cancer (2014) 0.78
Treatment of diffuse large B cell lymphoma. Korean J Intern Med (2012) 0.78
B cell modulation in rheumatology. Curr Opin Pharmacol (2007) 0.77
Real time analysis of binding between Rituximab (anti-CD20 antibody) and B lymphoma cells. Anal Chem (2013) 0.77
Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study. Clin Lymphoma Myeloma Leuk (2010) 0.77
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL). Curr Hematol Malig Rep (2016) 0.77
Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse. MAbs (2014) 0.76
Cetuximab in the management of colorectal cancer. Biologics (2007) 0.76
Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas. Ther Adv Hematol (2016) 0.76
FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma. DNA Cell Biol (2014) 0.76
Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity. PLoS One (2011) 0.76
Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Ann Hematol (2009) 0.76
Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro. PLoS One (2015) 0.75
I-Tositumomab in lymphoma. Curr Oncol (2009) 0.75
Successful Long Term Eradication of Factor VIII Inhibitor in Patients with Acquired Haemophilia A in Saudi Arabia. Mediterr J Hematol Infect Dis (2012) 0.75
Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. Drug Des Devel Ther (2017) 0.75
Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy. Oncogene (2016) 0.75
Combating rituximab resistance by inducing ceramide/lysosome-involved cell death through initiation of CD20-TNFR1 co-localization. Oncoimmunology (2016) 0.75
Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster. Oncotarget (2015) 0.75
Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors: From antigen choice to clinical implementation. Sultan Qaboos Univ Med J (2012) 0.75
The Effect of FcγRIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study. Turk J Haematol (2015) 0.75
Efficacy of rituximab and plasmapharesis in an adult patient with antifactor H autoantibody-associated hemolytic uremic syndrome: A case report and literature review. Medicine (Baltimore) (2016) 0.75
Interindividual variability in the concentration-effect relationship of antilymphocyte globulins - a possible influence of FcgammaRIIIa genetic polymorphism. Br J Clin Pharmacol (2007) 0.75
The war on cancer: a report from the front lines. Proc (Bayl Univ Med Cent) (2006) 0.75
The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis (2013) 0.75
Biologics in dermatology: an integrated review. Indian J Dermatol (2014) 0.75
Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. Br J Clin Pharmacol (2017) 0.75
Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot. Eur J Pediatr (2017) 0.75
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood (2002) 8.76
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood (2004) 4.05
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology (2008) 3.98
Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med (2002) 3.83
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol (2008) 3.49
Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol (2003) 2.62
Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res (2004) 2.41
Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol (2007) 2.24
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol (2012) 2.15
M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol (2009) 2.06
Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment. Crit Rev Oncol Hematol (2007) 1.84
Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. Br J Clin Pharmacol (2014) 1.56
Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood (2011) 1.56
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica (2007) 1.54
Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit (2008) 1.42
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther (2011) 1.37
Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol (2009) 1.33
Pathophysiology of disk-related sciatica. I.--Evidence supporting a chemical component. Joint Bone Spine (2005) 1.28
Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol (2011) 1.28
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol (2006) 1.23
Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte. J Clin Oncol (2009) 1.21
2nd Charles Richet et Jules Héricourt workshop: therapeutic antibodies and anaphylaxis; May 31-June 1, 2011, Tours, France. MAbs (2011) 1.20
Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality. Crit Rev Oncol Hematol (2007) 1.18
An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit (2006) 1.17
Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol (2010) 1.15
Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol (2008) 1.12
IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet Genomics (2009) 1.11
Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol (2012) 1.08
Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol (2007) 1.05
Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma (2003) 1.05
VEGF polymorphisms are associated with an increasing risk of developing renal cell carcinoma. J Urol (2010) 1.04
t(14;18) Translocation: A predictive blood biomarker for follicular lymphoma. J Clin Oncol (2014) 1.02
Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res (2008) 1.01
Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. Blood (2010) 1.01
Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol (2007) 1.00
Fatal infusion reactions to cetuximab: role of immunoglobulin e-mediated anaphylaxis. J Clin Oncol (2011) 0.99
Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. Biol Blood Marrow Transplant (2010) 0.96
The airways, a novel route for delivering monoclonal antibodies to treat lung tumors. Pharm Res (2011) 0.96
Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients. Blood (2013) 0.95
An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics. Ther Drug Monit (2010) 0.94
Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood (2010) 0.93
Therapeutic antibodies and infectious diseases, Tours, France, November 20-22, 2012. MAbs (2013) 0.93
Pathophysiology of disk-related low back pain and sciatica. II. Evidence supporting treatment with TNF-alpha antagonists. Joint Bone Spine (2005) 0.93
Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. Clin Cancer Res (2011) 0.92
Rapid single-step FCGR3A genotyping based on SYBR Green I fluorescence in real-time multiplex allele-specific PCR. J Immunol Methods (2003) 0.90
The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica (2011) 0.88
The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab. J Immunol (2007) 0.87
Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica (2009) 0.87
Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis? Joint Bone Spine (2012) 0.87
Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action. Arch Ophthalmol (2012) 0.87
An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab. Ther Drug Monit (2009) 0.86
[Therapeutic monoclonal antibodies in the French community: let's get organized]. Med Sci (Paris) (2009) 0.85
Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. Cancer Immunol Immunother (2004) 0.85
Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study. Ther Drug Monit (2011) 0.84
Therapeutic antibodies in ophthalmology: old is new again. MAbs (2011) 0.83
Lepidopteran cells, an alternative for the production of recombinant antibodies? MAbs (2012) 0.83
Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks. Int J Radiat Oncol Biol Phys (2010) 0.83
A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial. Am J Hematol (2014) 0.83
Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol (2015) 0.82
Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients. Exp Hematol (2012) 0.82
Can sciatica induced by disc herniation be treated with tumor necrosis factor alpha blockade? Arthritis Rheum (2007) 0.82
Detection of antiranibizumab antibodies among patients with exudative age-related macular degeneration. Ophthalmologica (2014) 0.81
The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells. Exp Hematol (2012) 0.81
Risk in drug trials. Lancet (2006) 0.81
Porcine CD58: cDNA cloning and molecular dissection of the porcine CD58-human CD2 interface. Biochem Biophys Res Commun (2003) 0.81
No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease. Pharmacogenet Genomics (2006) 0.81
Association of donor TNFRSF6 (FAS) gene polymorphism with acute rejection in renal transplant patients: a case-control study. Nephrol Dial Transplant (2004) 0.80
Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models. Exp Hematol (2010) 0.80
Analysis of human CD4 T lymphocyte proliferation induced by porcine lymphoblastoid B cell lines. Xenotransplantation (2003) 0.80
Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies. MAbs (2013) 0.80
From Bretonneau to therapeutic antibodies, from specificity to specific remedies, Saint-Cyr-Sur-Loire, France, November 19, 2012. MAbs (2013) 0.79
Stem cell mobilization in idiopathic steroid-sensitive nephrotic syndrome. Pediatr Nephrol (2008) 0.79
Rituximab: a new therapeutic tool for primary immune thrombocytopenic purpura? Haematologica (2003) 0.79
Complement in antibody therapy: friend or foe? Blood (2009) 0.78
The active role played by xenogeneic endothelial cells in the indirect presentation pathway is not lymphocyte trans-co-stimulation. Transpl Int (2005) 0.76
Human choriocarcinoma cell resistance to natural killer lysis due to defective triggering of natural killer cells. Biol Reprod (2003) 0.76
Facial granulomatous nodules during etanercept treatment for psoriasis. Int J Dermatol (2009) 0.76
[Target antigens for therapeutic antibodies in oncology: many candidates, few successes]. Bull Cancer (2007) 0.76
FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymorphisms in a Caucasian population. MAbs (2012) 0.76
Immunoassays for measuring serum concentrations of monoclonal antibodies and anti-biopharmaceutical antibodies in patients. Ther Drug Monit (2017) 0.75
Interindividual variability in the concentration-effect relationship of antilymphocyte globulins - a possible influence of FcgammaRIIIa genetic polymorphism. Br J Clin Pharmacol (2007) 0.75
Lability of IgE Levels Early in Life. J Allergy (Cairo) (2011) 0.75
Influence of FcγRIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients. Pharmacogenet Genomics (2014) 0.75
Bacteria and HIT: a close connection? Blood (2011) 0.75
Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies. Blood (2005) 0.75
[Tumour angiogenesis inhibition by therapeutic monoclonal antibodies]. Med Sci (Paris) (2009) 0.75
[Monoclonal anti-CD20 antibody therapy]. Rev Prat (2004) 0.75
Intensive therapies in follicular non-Hodgkin lymphomas. Blood (2002) 0.75
Unexplained abuses of human IgG subclass denomination in antibody patents. BioDrugs (2014) 0.75
[Neonatal Fc receptor, key control of immunoglobulins biodistribution]. Med Sci (Paris) (2009) 0.75
[Monoclonals antibodies: a recent and major therapeutic advance]. Therapie (2009) 0.75
[Biomarkers and pharmacokinetic-pharmacodynamic studies of immunosuppressive agents]. Therapie (2004) 0.75
[Serotherapy, among therapeutic innovations and scientific progress in the late 19th and 20th centuries]. Rev Prat (2012) 0.75